<DOC>
	<DOC>NCT00556023</DOC>
	<brief_summary>The purpose of this study is to determine the safety and tolerability of different doses of CP-675,206 in combination with gemcitabine and to determine the maximum dose of CP-675,206 that is well tolerated when given in combination with gemcitabine to patients with advanced pancreatic cancer.</brief_summary>
	<brief_title>A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients with metastatic pancreatic cancer Patient must have adequate bone marrow, liver and kidney function Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1 Chemotherapy naive Inoperable pancreatic cancer Patient must not have received prior systemic therapy for pancreatic cancer Patient must not have previously received antiCTLA4 therapy History of chronic inflammatory or autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>interventional</keyword>
	<keyword>dose-finding</keyword>
</DOC>